The Role of Melatonin in Insomnia and Neurodegenerative Conditions: A Critical Study
DOI:
https://doi.org/10.56294/mw2025461Keywords:
Neurodegenerative Disease (ND), Melatonin (MLT), Pineal Gland (PG), Circadian rhythms (CR)Abstract
The subsequent leading cause of mortality, neurodegenerative diseases (ND), gradually reduces the capacity of the central or peripheral nervous system to function properly and think coherently. In contemporary culture, the primary goal of public health is ND prevention. Numerous physiological functions in the brain are regulated by the hormone Melatonin (MLT), It was generated in the Pineal Gland (PG). Circadian rhythms (CR), biomolecular oxidation, eliminating free radicals, and preventing neuroinflammation are some of these mechanisms. MLT has been proven to have a multitude of neuroprotective effects through altering signaling pathways and pathophysiological processes. Neurological disorders may cause lower MLT levels. MLT regulates itself, interacts with molecules, and affects biological processes in ND. We also discuss the therapeutic use of MLT in the management of neurodegenerative illnesses. This knowledge might lead to the development of cutting-edge therapeutic approaches for the treatment of different ND and further our understanding of how MLT controls the brain's Circadian Rhythm (CR).
References
1. Wongprayoon P, Govitrapong P. Melatonin receptor as a drug target for neuroprotection. Current Molecular Pharmacology. 2021 Apr 1;14(2):150-64. https://doi.org/10.2174/1874467213666200421160835
2. Loh D, Reiter RJ. Melatonin: regulation of biomolecular condensates in neurodegenerative disorders. Antioxidants. 2021 Sep 17;10(9):1483. https://doi.org/10.3390/antiox10091483
3. Kafle OP, Cheng S, Ma M, Li P, Cheng B, Zhang L, Wen Y, Liang C, Qi X, Zhang F. Identifying insomnia-related chemicals through integrative analysis of genome-wide association studies and chemical–genes interaction information. Sleep. 2020 Sep 1;43(9):zsaa042. https://doi.org/10.1093/sleep/zsaa042
4. Cardinali DP. Melatonin: clinical perspectives in neurodegeneration. Frontiers in endocrinology. 2019 Jul 16;10:480. https://doi.org/10.3389/fendo.2019.00480
5. Wongchitrat P, Shukla M, Sharma R, Govitrapong P, Reiter RJ. Role of melatonin on virus-induced neuropathogenesis—a concomitant therapeutic strategy to understand SARS-CoV-2 infection. Antioxidants. 2021 Jan 2;10(1):47. https://doi.org/10.3390/antiox10010047
6. Polyakova VO, Kvetnoy IM, Anderson G, Rosati J, Mazzoccoli G, Linkova NS. Reciprocal interactions of mitochondria and the neuroimmunoendocrine system in neurodegenerative disorders: An important role for melatonin regulation. Frontiers in physiology. 2018 Mar 12;9:199. https://doi.org/10.3389/fphys.2018.00199
7. Spinedi E, Cardinali DP. Neuroendocrine-metabolic dysfunction and sleep disturbances in neurodegenerative disorders: focus on Alzheimer’s disease and melatonin. Neuroendocrinology. 2019 Jun 12;108(4):354-64. https://doi.org/10.1159/000494889
8. Yousaf T, Pagano G, Wilson H, Politis M. Neuroimaging of sleep disturbances in movement disorders. Frontiers in Neurology. 2018 Sep 11;9:767. https://doi.org/10.3389/fneur.2018.00767
9. Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. British journal of pharmacology. 2018 Aug;175(16):3190-9. https://doi.org/10.1111/bph.14116
10. Vecchierini MF, Kilic-Huck U, Quera-Salva MA. Melatonin (MEL) and its use in neurological diseases and insomnia: Recommendations of the French Medical and Research Sleep Society (SFRMS). Revue Neurologique. 2021 Mar 1;177(3):245-59. https://doi.org/10.1016/j.neurol.2020.06.009
11. Cahan JG, Abbott SM. Use of light therapy for insomnia in the elderly: role of circadian rhythm disorders. Current Sleep Medicine Reports. 2020 Sep;6:176-83. https://doi.org/10.1007/s40675-020-00181-z
12. Ferlazzo N, Andolina G, Cannata A, Costanzo MG, Rizzo V, Currò M, Ientile R, Caccamo D. Is melatonin the cornucopia of the 21st century?. Antioxidants. 2020 Nov;9(11):1088. https://doi.org/10.3390/antiox9111088
13. Kopustinskiene DM, Bernatoniene J. Molecular mechanisms of melatonin-mediated cell protection and signaling in health and disease. Pharmaceutics. 2021 Jan 20;13(2):129. https://doi.org/10.3390/pharmaceutics13020129
14. Palagini L, Manni R, Aguglia E, Amore M, Brugnoli R, Bioulac S, Bourgin P, Micoulaud Franchi JA, Girardi P, Grassi L, Lopez R. International expert opinions and recommendations on the use of melatonin in the treatment of insomnia and circadian sleep disturbances in adult neuropsychiatric disorders. Frontiers in psychiatry. 2021 Jun 10;12:688890. https://doi.org/10.3389/fpsyt.2021.688890
15. Kinoshita C, Okamoto Y, Aoyama K, Nakaki T. MicroRNA: a key player for the interplay of circadian rhythm abnormalities, sleep disorders and neurodegenerative diseases. Clocks & sleep. 2020 Jul 23;2(3):282-307. https://doi.org/10.3390/clockssleep2030022
16. Paulose JK, Wang C, O’Hara BF, Cassone VM. The effects of aging on sleep parameters in a healthy, melatonin-competent mouse model. Nature and Science of Sleep. 2019 Aug 12:113-21. https://doi.org/10.2147/NSS.S214423
17. Ferini-Strambi L, Galbiati A, Casoni F, Salsone M. Therapy for insomnia and circadian rhythm disorder in Alzheimer disease. Current treatment options in neurology. 2020 Feb;22:1-8. https://doi.org/10.1007/s11940-020-0612-z
18. Wongchitrat P, Shukla M, Sharma R, Govitrapong P, Reiter RJ. Role of melatonin on virus-induced neuropathogenesis—a concomitant therapeutic strategy to understand SARS-CoV-2 infection. Antioxidants. 2021 Jan 2;10(1):47. https://doi.org/10.3390/antiox10010047
19. Yang S, Wang J, Wang D, Guo L, Yu D. Melatonin receptor agonist ramelteon suppresses lps-induced neuroinflammation in astrocytes. ACS Chemical Neuroscience. 2021 Apr 20;12(9):1498-505. https://doi.org/10.1021/acschemneuro.0c00743
20. Kuthati Y, Lin SH, Chen J, Wong CS. Melatonin and their analogs as a potential use in the management of Neuropathic pain. Journal of the Formosan Medical Association. 2019 Aug 1;118(8):1177-86. https://doi.org/10.1016/j.jfma.2018.09.017
21. Hsu CN, Huang LT, Tain YL. Perinatal use of melatonin for offspring health: Focus on cardiovascular and neurological diseases. International journal of molecular sciences. 2019 Nov 13;20(22):5681. https://doi.org/10.3390/ijms20225681
22. Biggio G, Biggio F, Talani G, Mostallino MC, Aguglia A, Aguglia E, Palagini L. Melatonin: from neurobiology to treatment. Brain Sciences. 2021 Aug 25;11(9):1121. https://doi.org/10.3390/brainsci11091121
23. Li T, Jiang S, Lu C, Yang W, Yang Z, Hu W, Xin Z, Yang Y. Melatonin: another avenue for treating osteoporosis?. Journal of pineal research. 2019 Mar;66(2):e12548. https://doi.org/10.1111/jpi.12548
24. Zhang F, Niu L, Liu X, Liu Y, Li S, Yu H, Le W. Rapid eye movement sleep behavior disorder and neurodegenerative diseases: an update. Aging and disease. 2020 Mar 9;11(2):315. https://doi.org/10.14336/AD.2019.0324
25. Lee JG, Woo YS, Park SW, Seog DH, Seo MK, Bahk WM. The neuroprotective effects of melatonin: Possible role in the pathophysiology of neuropsychiatric disease. Brain sciences. 2019 Oct 21;9(10):285. https://doi.org/10.3390/brainsci9100285
26. Bah TM, Goodman J, Iliff JJ. Sleep as a therapeutic target in the aging brain. Neurotherapeutics. 2019 Jul 15;16:554-68. https://doi.org/10.1007/s13311-019-00769-6
27. Manni R, Cremascoli R, Perretti C, De Icco R, Picascia M, Ghezzi C, Cerri S, Sinforiani E, Terzaghi M. Evening melatonin timing secretion in real life conditions in patients with Alzheimer disease of mild to moderate severity. Sleep Medicine. 2019 Nov 1;63:122-6. https://doi.org/10.1016/j.sleep.2019.04.018
28. Madari S, Golebiowski R, Mansukhani MP, Kolla BP. Pharmacological management of insomnia. Neurotherapeutics. 2021 Jan 1;18(1):44-52. https://doi.org/10.1007/s13311-021-01010-z
29. Stefano GB, Pilonis N, Ptacek R, Raboch J, Vnukova M, Kream RM. Gut, microbiome, and brain regulatory axis: relevance to neurodegenerative and psychiatric disorders. Cellular and molecular neurobiology. 2018 Aug;38(6):1197-206. https://doi.org/10.1007/s10571-018-0589-2
30. Hou Y, Dan X, Babbar M, Wei Y, Hasselbalch SG, Croteau DL, Bohr VA. Ageing as a risk factor for neurodegenerative disease. Nature reviews neurology. 2019 Oct;15(10):565-81. https://doi.org/10.1007/s10571-018-0589-2
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Komal Parashar, Ashutosh Niranjan, Naresh Kaushik, Suvendu Narayan Mishra, Lokesh Ravilla, Madhur Grover (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
